STOP-AD: Five-Year Eczema Findings After Neonatal Emollient Use

Key Takeaways
- Among children recruited as high-familial-atopy-risk infants in Cork, Ireland, neonatal emollient assignment was associated with less clinically assessed atopic dermatitis at age five among those retained.
- Among children diagnosed with atopic dermatitis at the five-year visit, severity was significantly lower after neonatal emollient assignment.
- An imputed analysis pointed toward less atopic dermatitis after emollient assignment, but the association was not statistically significant.
- Retention at the five-year visit was lower in the emollient group than in the routine-care group.
The Short-Term Topical Application to Prevent Atopic Dermatitis (STOP-AD) cohort described in Cremin and colleagues' STOP-AD five-year follow-up came from a single-center, two-arm randomized trial at Cork University Maternity Hospital and Cork University Hospital in Ireland. Investigators randomized 321 term newborns with at least one parent reporting atopic dermatitis, asthma, or allergic rhinitis. Within four days of birth, infants were assigned twice-daily whole-body AVEENO Dermexa Fast & Long-Lasting Balm for eight weeks or routine skin-care advice.
At age five, blinded assessors used United Kingdom Working Party Diagnostic Criteria for an in-person point-prevalence diagnosis. The SCORing Atopic Dermatitis (SCORAD) severity index was applied only to confirmed cases. Of 179 children assessed, two were excluded after assessor unblinding, leaving 177 analyzed by original assignment. Investigators also used adjusted and imputed sensitivity approaches.
Among children assessed at age five, atopic dermatitis was diagnosed in 10/81 (12.3%) assigned emollient and 23/96 (24%) assigned routine skin care. These observations describe available cases, not every child originally randomized.
The primary comparison yielded a relative risk (RR) of 0.52, with a 95% confidence interval (CI) of 0.26–1.02 and p = .048. The reported p-value was below the conventional significance threshold, although the interval extended beyond 1. Adjusted complete-case estimates accounting for sex and parental atopy, and estimates restricted by early treatment use, pointed in the same direction.
Among children diagnosed with atopic dermatitis at the visit, median SCORAD was 12.0 (interquartile range [IQR] 8.2–15.2) after emollient assignment versus 19.6 (IQR 11.8–23.4) after routine-care assignment, p = .034. This severity comparison applies only to children with confirmed disease.
For all originally randomized infants, multiple imputation yielded an odds ratio (OR) of 0.45 (95% CI 0.19–1.03), p = .060. The association pointed in the same direction as the available-case comparison but was not statistically significant after accounting for missing outcomes.
Substantial follow-up loss, with lower retention in the intervention group, raises the possibility of differential selection; the imputed comparison leaves the longer-term association uncertain. The diagnosed severity subset was small, and the five-year outcome and longitudinal phenotype analyses were not prespecified. Emollient use after 12 months and topical corticosteroid use were not systematically captured. This single-center Irish cohort of children with familial atopic risk does not establish effects in unselected or U.S. populations, with other formulations, or under different later skin-care routines.
The investigators interpreted the lower observed atopic dermatitis prevalence and severity after neonatal emollient assignment as a possible persistent association, tempered by attrition and the inconclusive imputed comparison.
Clinician Questions
Was skin care restricted after the eight-week neonatal emollient intervention in STOP-AD?
After infants at familial risk of atopic dermatitis completed the eight-week randomized emollient-versus-routine-care period in STOP-AD, investigators provided no further intervention, specific skin-care guidance, or restrictions on emollient use before the five-year assessment. This does not establish which skin-care products families used afterward.
Did atopic dermatitis in infancy predict attendance at the STOP-AD five-year assessment?
Among children enrolled as high-familial-atopy-risk infants in STOP-AD, investigators found no association between atopic dermatitis status at six or 12 months and attendance at the five-year assessment in their reported logistic regressions. That finding does not rule out other causes of differential loss to follow-up.
Recommended Reading
- For more on childhood atopic dermatitis: Dupilumab Linked to Fewer New Atopic Diagnoses in Children
This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.